Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 25 of 30
Feb 26, 2026The pharmaceutical giant Boehringer Ingelheim has taken a significant step forward by partnering with Sitryx to enhance its immunology and inflammation therapeutic portfolio. This move highlights the strategic importance of oral small molecule drugs in tackling complex autoimmune disorders.
Feb 26, 2026Contract work is increasingly favored among biopharma employers and professionals alike. This article examines the growth of contract roles based on BioSpace data and features insights from three industry professionals sharing their experiences, benefits, and challenges with contracting.
Feb 25, 2026During a period of tight biotech capital markets, LB Pharma successfully completed one of the year’s most successful initial public offerings. This achievement highlights the resilience and strategic foresight of CEO Heather Turner and her team as they advanced a promising schizophrenia drug candidate.
Feb 24, 2026The recent price reduction by Novo Nordisk on its obesity drug portfolio prompts a nuanced discussion about whether this move truly benefits patients in terms of affordability and expanded access. This article delves into the market dynamics and potential implications for healthcare stakeholders.
Feb 24, 2026The oncology field faces significant challenges due to expensive drug waste. By employing data-driven approaches and better forecasting, stakeholders can optimize supply chain management and reduce financial losses, ultimately benefiting patients and payers alike.
Feb 23, 2026The lawsuit centers on allegations that Johnson & Johnson promoted its prostate cancer drug using flawed data, misrepresenting its effectiveness compared to Bayer’s competing treatments. This case highlights the intense competitive dynamics and the critical importance of accurate data in pharmaceutical marketing.
Feb 23, 2026The collaboration that began in 2022 on the cell therapy anito-cel has culminated in Gilead's acquisition of Arcellx, aiming to broaden its cancer treatment portfolio and provide patients with potentially safer and more effective options. This strategic move positions Gilead to compete more aggressively in the multiple myeloma market against established therapies.
Feb 23, 2026In a bold move, Novo Nordisk tested CagriSema against Lilly's already established obesity medication Zepbound before regulatory approval, a rare approach signaling aggressive competitive strategy. However, the trial outcome was unfavorable for Novo’s candidate drug, impacting the company’s ambitions in the obesity treatment landscape.
Feb 23, 2026The debut of Casgevy and Lyfgenia marked a pivotal moment in treating sickle cell disease with gene therapy. However, market challenges persist, as companies Vertex and Genetix Bio provide recent updates on their progress and hurdles in adoption.
Feb 19, 2026Many scientists who become CEOs may unintentionally move away from their foundational scientific principles when managing commercial innovations. Embracing a disciplined, scientific approach in business strategies can prevent common pitfalls, attract crucial investment, and accelerate the delivery of transformative technologies to the market.
Feb 18, 2026Historically known for collaborating in drug development, Ionis Pharmaceuticals charted a new course by bringing two medicines to market alone in 2025. Industry analysts are recognizing the company's strategic pivot and anticipate further progress in 2026.
Feb 18, 2026In a significant development for the biopharmaceutical industry and consumer safety, Bayer has reached a proposed $7.25 billion settlement addressing claims that its weedkiller Roundup caused cancer. This settlement represents one of the largest in the industry related to product liability and could have wide-reaching implications for regulatory practices and corporate responsibility in chemical and pharmaceutical product management.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.